Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

Arthritis & Rheumatism

Volumn 37, Issue 7, 1994, Pages 992-999

  Kavanaugh, Arthur F ^a   Davis, Laurie S ^b   Nichols, Lisa A ^b   Norris, Stephen H ^c   Rothlein, Robert ^d   Scharschmidt, Linda A ^d   Lipsky, Peter E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; C REACTIVE PROTEIN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; GOLD; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G2A; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BIRR 1; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CLONAL ANERGY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOSIS; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE; URTICARIA; VERTIGO;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CELL ADHESION MOLECULES; CELL COUNT; FEMALE; HUMAN; HYPERSENSITIVITY, DELAYED; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE SUBSETS; LYMPHOCYTES; MALE; MIDDLE AGE; MONOCYTES; NEUTROPHILS; PHENOTYPE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028355977     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780370703     Document Type: Article

References (32)

1. Rheumatoid arthritis: pathophysiology and implications for treatment
2. Severe functional declines, work disability, and increased mortality in seventy‐five rheumatoid arthritis patients studied over nine years
3. Rheumatoid arthritis: a disease of T‐lymphocyte/macrophage immunoregulation
4. Mechanisms of immune injury in rheumatoid arthritis: evidence for the involvement of T cells and heat‐shock protein
5. Clinical management of rheumatoid arthritis
6. Humanised monoclonal antibody therapy for rheumatoid arthritis
7. Adhesion molecules of the immune system
8. Membrane proteins involved in phagocyte adherence to endothelium
9. The role of CD11/CD18 in adhesion and transendothelial migration of T cells: analysis utilizing CD18 deficient T cell clones
10. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
11. Therapeutic criteria in rheumatoid arthritis
12. In vivo effects of monoclonal antibody to ICAM‐1 (CD54) in nonhuman primates with renal allografts
13. Phase I trial of immunosuppression with anti‐ICAM‐1 (CD54) mAb in renal allograft recipients
14. Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placebo
15. Self‐report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures
16. Leukocyte function‐associated antigen 1 is an activation molecule for human T cells
17. A human intercellular adhesion molecule (ICAM‐1) distinct from LFA‐1
18. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis
19. Association of the B‐cell alloantigen DRw4 with rheumatoid arthritis
20. Lymphapheresis in rheumatoid arthritis
21. The effect of thoracic duct drainage on lymphocyte dynamics and clinical symptoms in patients with rheumatoid arthritis
22. Treatment of intractable rheumatoid arthritis with total lymphoid irradiation
23. Cyclosporine A in severe, treatment refractory rheumatoid arthritis
24. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M‐T151: clinical results and immunopharmacologic effects in an open study, including repeated administration
25. Amelioration of antigen‐induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules
26. 1CAM‐1‐dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats
27. Intercellular adhesion molecule‐1 (ICAM‐1) in the pathogenesis of asthma
28. The use of monoclonal antibodies to achieve immunological tolerance
29. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM‐1 and LFA‐1
30. Regulation of the expression of adhesion molecules by human synoviocytes
31. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis
32. A CD18 monoclonal antibody increases the incidence and severity of subcutaneous abscess formation after high‐dose Staphylococcus aureus injection in rabbits